New hope for advanced skin cancers: first human trial launches
NCT ID NCT07600476
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This early-stage trial tests a new drug called KUP-101A in 21 people with advanced skin cancers (like melanoma or Merkel cell carcinoma) that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the body and whether it shows any signs of shrinking tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fachklinik Hornheide
RECRUITINGMünster, North Rhine-Westphalia, 48157, Germany
-
Universitätsklinikum Würzburg
RECRUITINGWürzburg, Bavaria, 97080, Germany
Conditions
Explore the condition pages connected to this study.